Rhythm Pharmaceuticals reports $60.1M Q1 sales for IMCIVREE, gains EU approval, and advances Japan review for obesity drug

Rhythm Pharmaceuticals reported $60.1 million in net product revenue from global sales of IMCIVREE in Q1 2026, marking a 5% increase from the previous quarter. The drug, approved in the U.S. for acquired hypothalamic obesity (HO), also received Marketing Authorization from the European Commission, with launches expected in 2027. Japan's regulatory review is underway, with a potential launch by the end of 2026. The company continues to develop related therapies and expects several clinical trial data readouts and regulatory milestones throughout 2026, supporting its long-term growth strategy.